Alentis Therapeutics’ Post

BCBN Feed: Takeda Announces Late-Breaking Data from Phase 2b Study of TAK-279, an Investigational, Oral, Once-Daily TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis at American College of Rheumatology Convergence Annual Meeting https://lnkd.in/gPPkfS7h OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the company will present positive results from its randomized, double-blind, placebo-controlled, Phase 2b trial evaluating TAK-279, an investigational oral allosteric tyrosine kinase 2 (TYK2) inhibitor with next generation selectivity, in patients with active psoriatic arthritis. These data (Abstract #L12) will... ... [...]

Aileron Therapeutics Reveals Cohort 1 Data from the P-Ib Clinical Evaluation of LTI-03 for Idiopathic Pulmonary Fibrosis (IPF) #ailerontherapeutics #lti03 #idiopathicpulmonaryfibrosis #clinicaltrial #phase1 #safety #efficacy #tolerability #inflammation #fibrosis #ipf

🚀𝐌𝐞𝐫𝐜𝐤’𝐬 𝐊𝐞𝐲𝐭𝐫𝐮𝐝𝐚 𝐧𝐚𝐛𝐬 𝐅𝐃𝐀 𝐧𝐨𝐝 𝐢𝐧 𝐛𝐢𝐥𝐢𝐚𝐫𝐲 𝐭𝐫𝐚𝐜𝐭 𝐜𝐚𝐧𝐜𝐞𝐫, 𝐜𝐚𝐭𝐜𝐡𝐢𝐧𝐠 𝐮𝐩 𝐰𝐢𝐭𝐡 𝐀𝐬𝐭𝐫𝐚𝐙𝐞𝐧𝐞𝐜𝐚’𝐬 𝐈𝐦𝐟𝐢𝐧𝐳𝐢💊 In November 2023, Merck Group KEYTRUDA® (pembrolizumab) HCP is on a winning streak scoring its sixth FDA (Food and Drug Administration) approval in #gastrointestinalcancers. The FDA (Food and Drug Administration) has based the approval on #data provided by company’s phase III keynote-966 trial that has shown its #Keytruda-chemo combo extended the #patients survival time as compared to the #chemotherapy. The Merck is proud to offer this #newtreatment option for biliary tract patients. 👉𝑹𝒆𝒍𝒂𝒕𝒆𝒅 𝑹𝒆𝒑𝒐𝒓𝒕:https://bit.ly/3tVa310 #Keytruda #Merck #AstraZeneca #Imfinzi #durvalumab #healthcare #prophecy #marketresearch #prophecymarketinsights

🔬𝗕𝗿𝗲𝗮𝗸𝘁𝗵𝗿𝗼𝘂𝗴𝗵 𝗶𝗻 𝗘𝗼𝘀𝗶𝗻𝗼𝗽𝗵𝗶𝗹𝗶𝗰 𝗘𝘀𝗼𝗽𝗵𝗮𝗴𝗶𝘁𝗶𝘀 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝘄𝗶𝘁𝗵 𝗕𝗲𝗻𝗿𝗮𝗹𝗶𝘇𝘂𝗺𝗮𝗯🌟   A recent study published in the New England Journal of Medicine highlights the efficacy of Benralizumab for treating eosinophilic esophagitis (EoE). This condition, characterized by high levels of eosinophils in the esophagus, often leads to chronic inflammation and difficulty swallowing.   𝐊𝐞𝐲 𝐅𝐢𝐧𝐝𝐢𝐧𝐠𝐬:   📉 Histologic Response The study revealed a significant histologic response in patients treated with Benralizumab. At week 24, 87.4% of patients showed a marked reduction in eosinophils compared to only 6.5% in the placebo group. This reduction is crucial as it indicates a decrease in inflammation and tissue damage.   👄 Symptom Improvement Although the histologic response was notable, the change in dysphagia (difficulty swallowing) symptoms did not significantly differ between the Benralizumab and placebo groups.   🛡️ Safety Profile The treatment was well-tolerated with a comparable rate of adverse events between the Benralizumab (64.1%) and placebo (61.7%) groups, and no trial discontinuations due to adverse effects.   These findings are promising for the EoE community, suggesting that while Benralizumab effectively reduces eosinophilic inflammation, further research is needed to translate this histological improvement into clinical symptom relief.   🔗 Read the full study here: https://lnkd.in/dBEAjiZr   Check our online shop (link in the comments) and discover the potential of clinical-grade molecules to improve research outcomes! #evidentic #antibody #mab #clinicalgrade #researchanddevelopment #drugdevelopment #drugdiscovery #betterhealth #pharmaceutical #mabs #monoclonalantibody #MedicalResearch #EosinophilicEsophagitis #Benralizumab #ClinicalTrials

At VascularStrategies, we are passionate about helping sponsors develop life-saving therapeutics for cardiovascular disease. To do this, we offer specialty and proprietary functional assays, useful for all phases of drug development, spanning bench to bedside. Our research and validated assays, and expert resources support you in moving your drug forward as quickly and cost-effectively as possible. Don’t miss out on #cardiovascularresearch updates. Follow us! #atherosclerosis #clinicalresearch #assays #drugdevelopment #hdl #frat

#Molecure's financial report for 2023 is now available on our website 📈 Here are some of the highlights: 💊 Initiation of Phase II clinical trial of #OATD01 (KITE) and world's first administration of a chitotriosidase 1 inhibitor (or placebo) to a patient with active pulmonary sarcoidosis at a hospital in the UK, following approval from the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA) 🔬 First success in #mRNA platform development - inhibited translation of pathogenic proteins in a cellular assay (in vitro proof-of-concept) 👩⚕ Further advances in the Phase I clinical trial of #OATD02, systematic dose escalation and and transition to a fourth cohort of patients with solid tumours 🚀 Further development of the most advanced project in the preclinical phase - the #USP7 inhibitor programme for use in anti-cancer therapies using artificial intelligence tools and models   Click here to view the full report (section "Raporty giełdowe") ➡ https://lnkd.in/djcwrXGn 

#ASCO24 #BreastCancer The DESTINY-Breast07 study serves as a prelude to DESTINY-Breast09. T-Dxd monotherapy and the combination of T-Dxd with pertuzumab have shown promising efficacy. Except for a higher incidence of grade 2 diarrhea with T-Dxd + pertuzumab compared to T-Dxd alone, the safety profile was favorable. The combination also demonstrated excellent ORR, especially CR, 12-month PFS, and efficacy regardless of disease and HR status. Question 1: How will Roche utilize the HER2 TKI ZN-1041 acquired from Zion Pharma Llc? Is Roche potentially entering the HER2+ mBC market where T-Dxd has already established a strong presence? At AACR23, AstraZeneca presented exciting findings. In HER2-low cell lines, treatment with irreversible inhibitors such as neratinib or afatinib resulted in more than a 50% reduction in surface HER2 levels due to increased internalization. Conversely, treatment with reversible inhibitors like lapatinib or tucatinib resulted in a 13-35% increase in surface HER2 levels. Irreversible HER2-TKIs can promote HER2 internalization, potentially enhancing T-Dxd binding to HER2. It's like getting on a moving carriage. https://lnkd.in/gsypamuy Question 2: The stratification factors for DESTINY-Breast07 include PD-L1 status, and although it has yet to be previously announced, Module 1 includes T-Dxd + Durvalumab. We've seen data on the T-Dxd + Durvalumab combination from the BEGONIA trial but not in HER2+ mBC. https://lnkd.in/gVxW9vDN

A biosimilar is a drug that’s highly similar to a biologic drug already authorized for sale. Biosimilars have been used safely for years. Health Canada has authorized biosimilar drugs for a range of conditions, including: • cancer • osteoporosis • Crohn’s disease • ulcerative colitis • rheumatoid arthritis Health Canada’s rigorous review standards mean that you can have the same trust in the quality, efficacy and safety of a biosimilar as in any other biologic drug. During #GlobalBiosimilarsWeek, we invite healthcare professionals to learn more about biosimilars and how Health Canada regulates them by consulting our new handbook on biosimilars: https://ow.ly/vEKf50Q8iGW

The answer to yesterday’s #ClinicalChallenge question is: D. A recent meta-analysis described the results of 25 clinical trials including over 10,000 patients with rheumatoid arthritis that compared biosimilar tumor necrosis factor (TNF)-alpha inhibitors with their reference biologic products, including infliximab, etanercept, and adalimumab. Biosimilars were equivalent to reference biologics in terms of disease activity (as measured by the American College of Rheumatology 20 response) and patient function (as measured by the Health Assessment Questionnaire Disability Index scores). Rheumatoid arthritis patients managed with TNF inhibitors can be reassured that biosimilars are as effective as bio-originators for the management of their disease. View the related What's New topic in #UpToDate: https://ow.ly/GLeB50Q7eVH #rheumatology #MedEd

#eua #FDA #novedadesregulatorias Today, FDA approved first interchangeable biosimilars to treat certain types of osteoporosis and prevent bone events in cancer. A biosimilar is a biological product that is highly similar to, and has no clinically meaningful differences from, a biological product already approved by FDA. This means patients can expect the same safety and effectiveness from the biosimilar. An interchangeable biosimilar is a biosimilar that has met other requirements under the law and may be substituted without consulting the prescriber. Biosimilar and interchangeable biosimilar products may cost less than the brand-name medicine. To learn more, visit: https://lnkd.in/eAQ76c8K https://lnkd.in/eJBCbc9i